AI TextQuick Glance (AI)Headnote
Issues: (i) Whether the respondent's cross-objections could challenge adverse portions of the order beyond the limited grounds raised in the Revenue's appeals; (ii) Whether the declared import values could be rejected on the basis of alleged control by the Malaysian entity, related-party relationship, parallel/proforma invoices, and alleged excess foreign-exchange remittances; (iii) Whether the revised retail sale price basis for additional customs duty was sustainable; (iv) Whether ConyTakara was classifiable as a medicament under CTH 3004 or as a skin-care preparation under CTH 3304.
Issue (i): Whether the respondent's cross-objections could challenge adverse portions of the order beyond the limited grounds raised in the Revenue's appeals.
Analysis: Section 129A(4) of the Customs Act, 1962 permits a respondent, notwithstanding that it has not independently appealed, to file cross-objections against any part of an order once an appeal against that order is filed. Such cross-objections must be disposed of as an appeal. The provision is not confined to rebutting only the grounds set out in the opposing party's appeal.
Conclusion: The cross-objections were maintainable and could challenge the substantive adverse findings in the impugned order.
Issue (ii): Whether the declared import values could be rejected on the basis of alleged control by the Malaysian entity, related-party relationship, parallel/proforma invoices, and alleged excess foreign-exchange remittances.
Analysis: No evidence established that shares were allotted to, or that administrative or financial control over the importer was exercised by, Conybio Malaysia. The alleged parallel invoices were proforma invoices and were unsupported by evidence of flowback or remittance exceeding the declared invoice values. The Malaysian suppliers and the Indian importer, being distinct juridical entities, could not be treated as family members under Rule 2(2)(viii) of the Customs Valuation Rules, 1988 merely because of relationships among their directors or shareholders. Nor was any other statutory basis for related-party treatment or proof that a relationship influenced price established. Consultancy payments were found to relate to services rendered and investment earnings could not be treated as additional import consideration.
Conclusion: Rejection of the declared transaction values and the consequential undervaluation demand were unsustainable, in favour of the assessee.
Issue (iii): Whether the revised retail sale price basis for additional customs duty was sustainable.
Analysis: The documentary invoices allegedly forming the basis for revised retail sale prices were not supplied to the importer, causing prejudice to its defence. Further, for the relevant pre-01.03.2008 period, no statutory machinery existed under Section 3(2) of the Customs Tariff Act, 1975 for post-import redetermination of the retail sale price of imported goods.
Conclusion: The additional customs duty demand based on revised retail sale prices was unsustainable, in favour of the assessee.
Issue (iv): Whether ConyTakara was classifiable as a medicament under CTH 3004 or as a skin-care preparation under CTH 3304.
Analysis: ConyTakara was a transdermal foot patch intended to provide therapeutic relief, detoxification and improved blood circulation. Its primary character was curative rather than cosmetic or for enhancement of appearance. The product therefore fell within the scope of medicaments, including transdermal administration systems, and did not satisfy the description of beauty or skin-care preparations.
Conclusion: ConyTakara is classifiable as a medicament under CTH 3004 and not under CTH 3304, in favour of the assessee.
Final Conclusion: The findings supporting undervaluation, related-party influence, retail sale price-based assessment, confiscability, and penalty lacked legal and evidentiary foundation; consequential relief follows.
Ratio Decidendi: Declared import value cannot be displaced on suspicion arising from proforma invoices, familial links between persons behind separate corporate entities, or unrelated remittances, without legally cognisable related-party status and evidence of additional consideration influencing the import price.
Customs valuation requires proof of price influence; unsupported related-party allegations and proforma invoices cannot displace declared import values.
Cross-objections under the Customs Act may challenge any adverse part of an order once an appeal is filed, not merely the appellant's grounds. Declared import values cannot be rejected without evidence of a statutory related-party relationship, price influence, additional consideration, or excess remittance; proforma invoices, relationships among persons behind separate entities, and consultancy or investment payments are insufficient. Post-import redetermination of retail sale price lacked statutory machinery for the relevant period, and undisclosed invoices prejudiced the importer's defence. A transdermal foot patch intended for therapeutic relief and improved circulation is classifiable as a medicament, not a skin-care preparation. Consequential undervaluation, confiscation and penalty findings lack foundation.
Scope of cross-objections - Rejection of declared transaction value - Post-import redetermination of retail sale price - Classification of therapeutic transdermal products - Redemption fine where goods are unavailable Scope of cross-objections - whether respondent's cross-objection under section 129A(4) can challenge the whole or any part of the order appealed against, notwithstanding that the respondent had not independently appealed? - HELD THAT: - The provision expressly permits a cross-objection against any part of the order appealed against and requires its disposal as if it were an appeal. Its scope is therefore not confined to answering the grounds raised in the opposite party's appeal. [Paras 7] The preliminary objection to the maintainability and scope of the cross-objections was overruled. Rejection of declared transaction value - Related persons under Customs Valuation Rules - Undervaluation based on proforma invoices - declared transaction values of Far Infrared BioCeramic healthcare products imported from the Malaysian suppliers rejected on the alleged relationship, parallel invoices, consultancy payments, or alleged excess foreign-exchange remittances - HELD THAT: - No evidence established allotment of shares or administrative and financial control by Conybio Malaysia over the importer. The alleged parallel invoices were proforma invoices unsupported by evidence of flow-back or remittance beyond the declared invoice values. Companies could not be treated as members of the same family merely because their directors or shareholders were related natural persons; nor did common directorship establish relationship. Payments under the consultancy arrangement and earnings on investments were not proved to be additional consideration for the imported goods. The Department consequently failed to establish either a relationship influencing price or payment in excess of the declared values. [Paras 12, 13, 14, 15] The undervaluation finding and consequential differential-duty demand, interest and penalties were held unsustainable. Post-import redetermination of retail sale price - Natural justice in retail sale price determination - additional customs duty demand founded on revised retail sale prices of the imported notified goods was sustainable neither on evidence nor in law - HELD THAT: - The invoices allegedly relied upon for determining the retail sale price were not furnished, causing prejudice to the importer's defence. Further, for the period concerned, there was no statutory machinery for post-import ascertainment or redetermination of retail sale price for levy of additional customs duty. [Paras 16] The demand based on revised retail sale price was set aside. Classification of therapeutic transdermal products - Medicament versus skin-care preparation - ConyTakara, a foot-applied sheet intended to relieve pain, promote blood circulation and detoxification, was classifiable as a medicament under CTH 3004 or as a skin-care product under CTH 3304 - HELD THAT: - The product's therapeutic and curative attributes, coupled with its form as a patch applied directly to the skin, brought it within the scope of medicaments. It was neither a beauty nor a make-up preparation for skin care, and the adjudicating authority had not established its exclusion from CTH 3004 or its inclusion under CTH 3304. [Paras 17] The declared classification under CTH 3004 was upheld and the proposed reclassification under CTH 3304 was rejected. Redemption fine where goods are unavailable - whether Redemption fine could be imposed in respect of imported goods that were unavailable, particularly when the underlying findings warranting confiscation were unsustainable? - HELD THAT: - As the findings of relationship and undervaluation were not proved, the conclusion that the goods were liable to confiscation could not survive. Independently, redemption fine was not imposable when the goods were unavailable. [Paras 19, 20] The Revenue's challenge to non-imposition of redemption fine and to non-inclusion of interest in penalty was rejected. Final Conclusion: The cross-objections were allowed, the impugned order was set aside, and the Department's appeals were rejected with consequential relief.